FIELD: medicine. SUBSTANCE: method involves applying composition containing immunotoxin possessing neoplastic activity. The immunotoxin is helonin and monoclonic body conjugate showing specific binding property with respect to c_ erb B-2 antigen domain being Tab 250. Composition having neoplastic activity is composed of immunotoxin and pharmaceutically acceptable carrier. Neoplastic cell treatment method involves introducing effective dose of immunotoxin into the cell. EFFECT: improved selectivity in delivering drug to cell. 10 cl, 7 dwg
